Onyia Jude 4

What Happened
Onyia Jude, a director of Voyager Therapeutics, was granted a derivative award of 30,000 shares on 2026-06-09. The Form 4 shows an acquisition type "A" (award/grant) at $0.00 (no cash paid at grant). The award was filed on 2026-06-11.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (appears timely).
• Instrument: stock option award (derivative); reported as 30,000 shares at $0.00.
• Vesting: per footnote F1, vesting commencement = grant date; all underlying shares vest upon the earlier of the one-year anniversary of the grant or the next annual meeting of stockholders, subject to continued service as a director.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Remarks/Exhibits: Exhibit 24 (Power of Attorney) included.

Context
This is a director compensation award under Voyager’s 2025 Stock Incentive Plan (routine for board members). It is an option/award grant—no immediate sale or purchase of common stock—so it reflects compensation rather than an open-market investment by the insider.